{
    "root": "e6e1419a-65f6-42a7-a4f9-67a2fdf7aa53",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Ciprofloxacin",
    "value": "20250228",
    "ingredients": [
        {
            "name": "CIPROFLOXACIN HYDROCHLORIDE",
            "code": "4BA73M5E37"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "HYPROMELLOSE 2910 (5 MPA.S)",
            "code": "R75537T0T4"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "POLYETHYLENE GLYCOL 400",
            "code": "B697894SGQ"
        },
        {
            "name": "POVIDONE K30",
            "code": "U725QWY32X"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        }
    ],
    "indications": "ciprofloxacin tablet fluoroquinolone antibacterial indicated adults ( 18 years age older ) following infections caused designated , susceptible bacteria pediatric patients indicated : • skin skin structure infections ( 1.1 ) • bone joint infections ( 1.2 ) • complicated intra-abdominal infections ( 1.3 ) • infectious diarrhea ( 1.4 ) • typhoid fever ( enteric fever ) ( 1.5 ) • uncomplicated cervical urethral gonorrhea ( 1.6 ) • inhalational anthrax post-exposure adult pediatric patients ( 1.7 ) • plague adult pediatric patients ( 1.8 ) • chronic bacterial prostatitis ( 1.9 ) • lower respiratory tract infections ( 1.10 ) acute exacerbation chronic bronchitis • urinary tract infections ( 1.11 ) urinary tract infections ( uti ) acute uncomplicated cystitis complicated uti pyelonephritis pediatric patients • acute sinusitis ( 1.12 ) usage reduce development drug-resistant bacteria maintain effectiveness ciprofloxacin tablets antibacterial drugs , ciprofloxacin tablets used treat prevent infections proven strongly suspected caused bacteria . ( 1.13 )",
    "contraindications": "ciprofloxacin tablets administered orally described appropriate guidelines tables .",
    "warningsAndPrecautions": "ciprofloxacin tablets usp , 500 mg available white off-white , capsule shaped film coated tablets debossed ‘ c ’ one side ‘ 94 ’ side . bottles 6 ndc 68788-8136-0 bottles 10 ndc 68788-8136-8 bottles 14 ndc 68788-8136-1 bottles 20 ndc 68788-8136-2 bottles 30 ndc 68788-8136-3 store 20° 25°c ( 68° 77°f ) ; excursions permitted 15° 30°c ( 59° 86°f ) [ usp controlled room temperature ] .",
    "adverseReactions": "• known hypersensitivity ciprofloxacin tablets quinolones ( 4.1 , 5.6 , 5.7 ) • concomitant tizanidine ( 4.2 )",
    "indications_original": "Ciprofloxacin tablet is a fluoroquinolone antibacterial indicated in adults (18 years of age and older) with the following infections caused by designated, susceptible bacteria and in pediatric patients where indicated: • Skin and Skin Structure Infections ( 1.1 ) • Bone and Joint Infections ( 1.2 ) • Complicated Intra-Abdominal Infections ( 1.3 ) • Infectious Diarrhea ( 1.4 ) • Typhoid Fever (Enteric Fever) ( 1.5 ) • Uncomplicated Cervical and Urethral Gonorrhea ( 1.6 ) • Inhalational Anthrax post-exposure in adult and pediatric patients ( 1.7 ) • Plague in adult and pediatric patients ( 1.8 ) • Chronic Bacterial Prostatitis ( 1.9 ) • Lower Respiratory Tract Infections ( 1.10 ) o Acute Exacerbation of Chronic Bronchitis • Urinary Tract Infections ( 1.11 ) o Urinary Tract Infections (UTI) o Acute Uncomplicated Cystitis o Complicated UTI and Pyelonephritis in Pediatric Patients • Acute Sinusitis ( 1.12 ) Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of ciprofloxacin tablets and other antibacterial drugs, ciprofloxacin tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.13 )",
    "contraindications_original": "Ciprofloxacin tablets should be administered orally as described in the appropriate Dosage Guidelines tables.",
    "warningsAndPrecautions_original": "Ciprofloxacin Tablets USP, 500 mg are available as white to off-white, capsule shaped film coated tablets debossed with ‘C’ on one side and ‘94’ on the other side.\n                              Bottles of 6                                       NDC 68788-8136-0\n                          Bottles of 10                                       NDC 68788-8136-8\n                          Bottles of 14                                       NDC 68788-8136-1\n                          Bottles of 20                                       NDC 68788-8136-2\n                          Bottles of 30                                       NDC 68788-8136-3\n                     \n                     \n                      Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].",
    "adverseReactions_original": "• Known hypersensitivity to ciprofloxacin tablets or other quinolones ( 4.1 , 5.6 , 5.7 ) • Concomitant administration with tizanidine ( 4.2 )"
}